Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
02:00pm, Wednesday, 16'th Apr 2025
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm
11:03am, Thursday, 10'th Apr 2025
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) bre
Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?
10:55am, Thursday, 10'th Apr 2025
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm
02:03pm, Tuesday, 08'th Apr 2025
NEW YORK , April 8, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) breac
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
07:00am, Tuesday, 08'th Apr 2025
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a
Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation
AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol
12:30pm, Wednesday, 02'nd Apr 2025
Axsome's phase III PARADIGM study evaluating solriamfetol in major depressive disorder fails to show a statistically significant change in the primary endpoint.
Why Shares of Axsome Therapeutics Slumped Today
01:23pm, Tuesday, 01'st Apr 2025
Shares of biopharmaceutical company Axsome Therapeutics (AXSM -6.29%) had declined 6% at 11 a.m. ET today. The slump comes after the company announced the results of a phase 3 trial of solriamfetol (b
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week
01:06pm, Tuesday, 01'st Apr 2025
Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive. The post Axsome Therapeutics Dives Again On Its Second Big Drug Failure In
Axsome's depression treatment fails to meet main goal of late-stage study
07:18am, Tuesday, 01'st Apr 2025
Axsome Therapeutics said on Tuesday its experimental drug to treat major depressive disorder failed to meet the main goal of a late-stage study.
AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint
12:55pm, Wednesday, 26'th Mar 2025
Axsome's phase III FOCUS study, evaluating solriamfetol for treating attention deficit hyperactivity disorder, meets its primary and key secondary endpoints.
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
06:47pm, Tuesday, 25'th Mar 2025
As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they trad
Axsome Therapeutics' ADHD drug meets main goal in late-stage study
07:13am, Tuesday, 25'th Mar 2025
Axsome Therapeutics said on Tuesday its experimental drug to treat attention deficit hyperactivity disorder (ADHD) met the main goal in a late-stage study.
Axsome: The Alzheimer's Agitation Program For AXS-05
11:36am, Friday, 21'st Mar 2025
Axsome's AXS-05 shows strong efficacy in treating Alzheimer's Disease Agitation, with significant CMAI score reductions in multiple Phase 3 trials. The FDA has greenlit Axsome to submit an sNDA for AX
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?
11:56am, Friday, 14'th Mar 2025
Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.
